CarelonRx: Specialty Pharmacy Trends & Insights
- The pipeline for specialty drugs is expanding, with numerous medications expected to gain approval.
- The FDA's Center for Drug Evaluation and Research (CDER) reports that roughly 50% of new drug approvals target rare conditions with unmet needs,leading to new spending.
- To assist patients and caregivers, effective specialty drug management shoudl prioritize cost control to ensure affordability, access, and clarity.
Navigate the evolving landscape of specialty pharmacy with expert insights. This article uncovers crucial strategies for effective specialty drug management, emphasizing clinical approaches and cost control in 2025 and beyond. Discover how CarelonRx is spearheading advancements in the field,prioritizing patient-centered care and optimizing access to life-changing medications. Addressing the rise of new specialty drugs targeting rare conditions, the article analyzes the impact of these innovations and provides actionable guidance for healthcare professionals. Explore the significance of a robust specialty pharmacy program and how it improves patient outcomes. This information, supported by credible data, is essential for navigating the complexities of specialty drug management. News directory 3 brings you the latest research and analyses.Discover what’s next in specialty pharmacy trends that will influence the future.
Specialty Drug Management: Strategies for 2025 and Beyond
Updated June 17, 2025
The pipeline for specialty drugs is expanding, with numerous medications expected to gain approval. Healthcare leaders must understand the clinical benefits and potential harms compared to existing treatments. Establishing clear guidelines and preparing for associated costs are also crucial to help patients with complex illnesses who could benefit from these new drugs.
The FDA’s Center for Drug Evaluation and Research (CDER) reports that roughly 50% of new drug approvals target rare conditions with unmet needs,leading to new spending. IQVIA reports that specialty medicines now account for over half of all medication spending.
To assist patients and caregivers, effective specialty drug management shoudl prioritize cost control to ensure affordability, access, and clarity. CarelonRx pharmacists are focusing on three core areas when analyzing trends and strategies in the evolving specialty pharmacy landscape.
A clinical approach is essential,with drug placement resolute by administration method. Self-injected and oral drugs fall under pharmacy benefits, while physician-administered drugs are covered under medical benefits. Strategies should remain consistent across benefits, as treatments often span both categories.
Consider chronic obstructive pulmonary disease (COPD), which affects about 16 million U.S. adults. While treatment typically involves inhaled therapies and oral steroids, the introduction of Dupixent, the first biologic approved for COPD, is changing the landscape.
Approximately 2% of Americans with COPD may be candidates for biologics. Monitoring biologics could lead to better patient outcomes and reduced costs from fewer exacerbations and hospitalizations. these treatments may also improve adherence due to less frequent administration.
Though,the introduction of new biologics into COPD treatment is expected to increase drug spending due to their high annual cost and broader adoption of newer inhaled therapies. Sales of COPD biologics are projected to triple by 2033.
Since COPD has primarily been managed with inhaled therapies, specialty pharmacy programs can assist patients adopting self-injectables by ensuring access and affordability, which are vital for successful clinical outcomes.
Monitoring new medications, such as those for COPD, is